Xiaoping Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaoping Wang has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Huan-Ping Lin
Laboratory of Molecular Biology & Pathology, Shaanxi University of Chinese Medicine, Xianyang, China
1 shared publicationHuanping Lin
1 shared publication- Huanping Lin
Laboratory of Molecular Pathology, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi, China
1 shared publication Lijun Sun
1 shared publicationQiao-Xia Wang
Department of Infectious Diseases, Xi'an Central Hospital, Xi'an Jiaotong University, Xi'an, China
1 shared publicationQiaoxia Wang
1 shared publication
Latest Publications
- 1 June 2013
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 28 (5) , 406-414
Glycoprotein 96 and α-Fetoprotein Cross-Linking Complexes Elicited Specific Antitumor Immunity
Hepatocellular carcinoma (HCC) is one of the most common malignant gastroenterological cancers over the world. α-fetoprotein (AFP) is an oncofetal protein produced during HCC development that could generate weaker and less reproducible antitumor protection, and it may serve as a target for immunotherapy. Therefore, it is imperative to enhance its immunogenicity and develop therapeutic vaccines to eliminate AFP-expressing tumors. In this study, by way of glutaraldehyde cross-linking, we constructed a potential therapeutic protein vaccine, glycoprotein 96 (gp96)/AFP. Our results demonstrated that AFP and gp96 synergistically exhibited significant increase in AFP-specific CD8+ T-cell responses and impressive cytotoxic antitumor effect against AFP-expressing tumors. Priming mice with the reconstructed vaccine, we elicited robust strong protective immunity. Our study suggests that tumor vaccine by cross-linking tumor antigen and gp96 is a promising approach to cancer therapy.
- 1 June 2013
- Published by SAGE Publications in Cancer Biotherapy and Radiopharmaceuticals
- Vol. 28 (5) , 406-414
Glycoprotein 96 and α-Fetoprotein Cross-Linking Complexes Elicited Specific Antitumor Immunity
Hepatocellular carcinoma (HCC) is one of the most common malignant gastroenterological cancers over the world. α-fetoprotein (AFP) is an oncofetal protein produced during HCC development that could generate weaker and less reproducible antitumor protection, and it may serve as a target for immunotherapy. Therefore, it is imperative to enhance its immunogenicity and develop therapeutic vaccines to eliminate AFP-expressing tumors. In this study, by way of glutaraldehyde cross-linking, we constructed a potential therapeutic protein vaccine, glycoprotein 96 (gp96)/AFP. Our results demonstrated that AFP and gp96 synergistically exhibited significant increase in AFP-specific CD8+ T-cell responses and impressive cytotoxic antitumor effect against AFP-expressing tumors. Priming mice with the reconstructed vaccine, we elicited robust strong protective immunity. Our study suggests that tumor vaccine by cross-linking tumor antigen and gp96 is a promising approach to cancer therapy.
- 1 February 2013
- Published by Elsevier in Clinica Chimica Acta
- Vol. 417, 73-79
HSP72 and gp96 in gastroenterological cancers
- 1 February 2013
- Published by Elsevier in Clinica Chimica Acta
- Vol. 417, 73-79
HSP72 and gp96 in gastroenterological cancers
- Open Access
- 1 January 2012
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 11 (1) , 25
Multiple roles of dihomo-γ-linolenic acid against proliferation diseases
Considerable arguments remain regarding the diverse biological activities of polyunsaturated fatty acids (PUFA). One of the most interesting but controversial dietary approaches focused on the diverse function of dihomo-dietary γ-linolenic acid (DGLA) in anti-inflammation and anti-proliferation diseases, especially for cancers. This strategy is based on the ability of DGLA to interfere in cellular lipid metabolism and eicosanoid (cyclooxygenase and lipoxygenase) biosynthesis. Subsequently, DGLA can be further converted by inflammatory cells to 15-(S)-hydroxy-8,11,13-eicosatrienoic acid and prostaglandin E1 (PGE1). This is noteworthy because these compounds possess both anti-inflammatory and anti-proliferative properties. PGE1 could also induce growth inhibition and differentiation of cancer cells. Although the mechanism of DGLA has not yet been elucidated, it is significant to anticipate the antitumor potential benefits from DGLA.
- 1 January 2012
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 11 (1) , 25
Open AccessMultiple roles of dihomo-γ-linolenic acid against proliferation diseases
Considerable arguments remain regarding the diverse biological activities of polyunsaturated fatty acids (PUFA). One of the most interesting but controversial dietary approaches focused on the diverse function of dihomo-dietary γ-linolenic acid (DGLA) in anti-inflammation and anti-proliferation diseases, especially for cancers. This strategy is based on the ability of DGLA to interfere in cellular lipid metabolism and eicosanoid (cyclooxygenase and lipoxygenase) biosynthesis. Subsequently, DGLA can be further converted by inflammatory cells to 15-(S)-hydroxy-8,11,13-eicosatrienoic acid and prostaglandin E1 (PGE1). This is noteworthy because these compounds possess both anti-inflammatory and anti-proliferative properties. PGE1 could also induce growth inhibition and differentiation of cancer cells. Although the mechanism of DGLA has not yet been elucidated, it is significant to anticipate the antitumor potential benefits from DGLA.